litlas
ログインアカウント作成

Jonathan W. Friedberg

1995–2025 年に発表

別表記
Jonathan W Friedberg
142
論文数
26,693
被引用数
81
h 指数
135
i10 指数

被引用数

Jonathan W. Friedberg の年別被引用数1978 年: 被引用 1 件1986 年: 被引用 1 件1992 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 8 件2002 年: 被引用 4 件2003 年: 被引用 18 件2004 年: 被引用 24 件2005 年: 被引用 41 件2006 年: 被引用 44 件2007 年: 被引用 49 件2008 年: 被引用 45 件2009 年: 被引用 54 件2010 年: 被引用 65 件2011 年: 被引用 80 件2012 年: 被引用 96 件2013 年: 被引用 103 件2014 年: 被引用 89 件2015 年: 被引用 133 件2016 年: 被引用 120 件2017 年: 被引用 172 件2018 年: 被引用 242 件2019 年: 被引用 910 件2020 年: 被引用 1,096 件2021 年: 被引用 1,103 件2022 年: 被引用 956 件2023 年: 被引用 753 件2024 年: 被引用 1,337 件2025 年: 被引用 607 件2026 年: 被引用 10 件1979〜1985 年は被引用が無いため表示していません1987〜1991 年は被引用が無いため表示していません1993〜1997 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,400 件、この内訳の 29.6%中国: 引用元論文 1,006 件、この内訳の 8.8%ドイツ: 引用元論文 719 件、この内訳の 6.3%イギリス: 引用元論文 652 件、この内訳の 5.7%フランス: 引用元論文 620 件、この内訳の 5.4%イタリア: 引用元論文 614 件、この内訳の 5.3%スペイン: 引用元論文 450 件、この内訳の 3.9%カナダ: 引用元論文 427 件、この内訳の 3.7%スイス: 引用元論文 356 件、この内訳の 3.1%オーストラリア: 引用元論文 298 件、この内訳の 2.6%オランダ: 引用元論文 290 件、この内訳の 2.5%日本: 引用元論文 247 件、この内訳の 2.1%
0%29.6%その他 21%

機関

分野

  • Medicine86.1%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Immunology and Microbiology5.3%
  • Engineering0.4%
  • Computer Science0.3%
  • Materials Science0.2%
  • その他1%

トピック

  • CAR-T cell therapy research16.8%
  • Lymphoma Diagnosis and Treatment13.7%
  • Chronic Lymphocytic Leukemia Research4.2%
  • Immune Cell Function and Interaction4.1%
  • Virus-based gene therapy research3.9%
  • CNS Lymphoma Diagnosis and Treatment3.3%
  • その他54%

共著者

全論文

検索で開く
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    著者: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 被引用: 5,915

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    著者: Elı́as Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Doǧan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesús F. San Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana H. Advani, Stephen M. Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 被引用: 1,506

  3. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    著者: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 被引用: 843

  4. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

    著者: Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Długosz‐Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana H. Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon‐Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus - New England Journal of Medicine 2022 被引用: 328

  5. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    著者: James N. Kochenderfer, Robert Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John M. Rossi, Allen Xue, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Marika Sherman, Arianne Perez, Constance M. Yuan, Tatyana Feldman, Jonathan W. Friedberg, Mark Roschewski, Steven A. Feldman, Lori McIntyre, Mary Ann Toomey, Steven A. Rosenberg - Journal of Clinical Oncology 2017 被引用: 561

  6. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    著者: Carla Casulo, Michelle Byrtek, Keith Dawson, Xiaolei Zhou, Charles M. Farber, Christopher R. Flowers, John D. Hainsworth, Matthew J. Maurer, James R. Cerhan, Brian K. Link, Andrew D. Zelenetz, Jonathan W. Friedberg - Journal of Clinical Oncology 2015 被引用: 844

  7. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    著者: Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski ほか 69 名 - The Lancet 2018 被引用: 726

  8. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    著者: Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi Pederson, Mei‐Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner‐Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha Reddy, Jane N. Winter, Julie Chang, Ajay K. Gopal, Amy Chadburn, Susan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schöder, Andrew D. Zelenetz, John P. Leonard - Journal of Clinical Oncology 2019 被引用: 423

  9. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    著者: Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby‐Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma Rodriguez, Auayporn Nademanee, Mark Kaminski, Myron S. Czuczman, Michael Millenson, Joyce C. Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter - Blood 2013 被引用: 953

  10. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

    著者: Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, David Hodgson, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joo Y. Song, Richard F. Little, Brad S. Kahl, John P. Leonard, Kara M. Kelly, Sonali M. Smith, Jonathan W. Friedberg - Journal of Clinical Oncology 2023 被引用: 117

  11. Classical Hodgkin lymphoma

    著者: Pauline Brice, Eric de Kerviler, Jonathan W Friedberg - The Lancet 2021 被引用: 162

  12. Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    著者: Jonathan W. Friedberg - Hematology 2011 被引用: 502

  13. Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

    著者: Sven de Vos, John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy, Rod Humerickhouse, John Hayslip, John C. Pesko, Wyndham H. Wilson - Leukemia & lymphoma/Leukemia and lymphoma 2020 被引用: 93

  14. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

    著者: Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Matthew Mei, Brian Hess, Ryan Jacobs, Hayder Saeed, Pallawi Torka, Boyu Hu, Craig H. Moskowitz, Supreet Kaur, Gaurav Goyal, Christopher J. Forlenza, Andrew Doan, Adam J. Lamble, Pankaj Kumar, Saeeda Chowdhury, Brett T. Brinker, Namita Sharma, Avina K. Singh, Kristie A. Blum, Anamarija M. Perry, Alexandra E. Kovach, David Hodgson, Louis S. Constine, Lale Kostakoglu Shields, Anca Prica, Hildy Dillon, Richard F. Little, Margaret A. Shipp, Michael Crump, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Joo Y. Song, Kara M. Kelly, Jonathan W. Friedberg - New England Journal of Medicine 2024 被引用: 200

  15. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

    著者: Kieron Dunleavy, Michelle A. Fanale, Jeremy S Abramson, Ariela Noy, Paolo F. Caimi, Stefania Pittaluga, Samir Parekh, Ann S. LaCasce, John W. Hayslip, Deepa Jagadeesh, Sunil Nagpal, Mary Jo Lechowicz, Rakesh Gaur, Andrea N. Lucas, Christopher Melani, Mark Roschewski, Seth M. Steinberg, Elaine S. Jaffe, Brad S. Kahl, Jonathan W. Friedberg, Richard F. Little, Nancy L. Bartlett, Wyndham H. Wilson - The Lancet Haematology 2018 被引用: 232

  16. In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

    著者: Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg, Debra K. Czerwinski, Steven Long, Richard T. Hoppe, Robert S. Janssen, Albert F. Candia, Robert L. Coffman, Ronald Levy - Cancer Discovery 2018 被引用: 188

  17. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

    著者: Vindi Jurinović, Robert Kridel, Annette M. Staiger, Monika Szczepanowski, Heike Horn, Martin Dreyling, Andreas Rosenwald, German Ott, Wolfgang Hiddemann, Andrew D. Zelenetz, Paul M. Barr, Jonathan W. Friedberg, Stephen M. Ansell, Laurie H. Sehn, Joseph M. Connors, Randy D. Gascoyne, Wolfgang Hiddemann, Michael Unterhalt, David M. Weinstock, Oliver Weigert - Blood 2016 被引用: 229

  18. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

    著者: Nina D. Wagner‐Johnston, Brian K. Link, Michelle Byrtek, Keith Dawson, John D. Hainsworth, Christopher R. Flowers, Jonathan W. Friedberg, Nancy L. Bartlett - Blood 2015 被引用: 218

  19. Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

    著者: Brian K. Link, Bann‐Mo Day, Xiaolei Zhou, Andrew D. Zelenetz, Keith Dawson, James R. Cerhan, Christopher R. Flowers, Jonathan W. Friedberg - British Journal of Haematology 2018 被引用: 97

  20. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

    著者: Mark Roschewski, Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel, Philip J. Bierman, Deepa Jagadeesh, Ronald T. Mitsuyasu, David Peace, Peter R. Watson, Wahid T. Hanna, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Stefania Pittaluga, Elaine S. Jaffe, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Michelle A. Fanale, Ariela Noy, Wyndham H. Wilson - Journal of Clinical Oncology 2020 被引用: 150

  21. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

    著者: Heiko Schöder, Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary J. Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina D. Wagner‐Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett - Blood 2020 被引用: 94

  22. Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

    著者: Daniel O. Persky, Hongli Li, Deborah M. Stephens, Steven I. Park, Nancy L. Bartlett, Lode J. Swinnen, Paul M. Barr, Jerome D. Winegarden, Louis S. Constine, Thomas J. FitzGerald, John P. Leonard, Brad S. Kahl, Michael LeBlanc, Joo Y. Song, Richard I. Fisher, Lisa M. Rimsza, Sonali M. Smith, Thomas P. Miller, Jonathan W. Friedberg - Journal of Clinical Oncology 2020 被引用: 128

  23. Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells

    著者: Andrew G. Evans, Paul G. Rothberg, Richard Burack, Scott F. Huntington, David L. Porter, Jonathan W. Friedberg, Jane L. Liesveld - British Journal of Haematology 2015 被引用: 105

  24. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    著者: Leo I. Gordon, Fangxin Hong, Richard I. Fisher, Nancy L. Bartlett, Joseph M. Connors, Randy D. Gascoyne, Henry Wagner, Patrick J. Stiff, Bruce D. Cheson, Mary Gospodarowicz, Ranjana H. Advani, Brad S. Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph M. Tuscano, Richard T. Hoppe, Sandra J. Horning - Journal of Clinical Oncology 2012 被引用: 309